肺腺鳞癌(adenosquamous carcinoma of the lung, ASC)是一种罕见但又独特的非小细胞肺癌(NSCLC)特殊类型,具有恶性程度高、侵袭性强、预后差、治疗难度大等特点。随着对ASC发病机制的深入研究,不断有新的治疗策略被开发出来。目前对于...
详细信息
肺腺鳞癌(adenosquamous carcinoma of the lung, ASC)是一种罕见但又独特的非小细胞肺癌(NSCLC)特殊类型,具有恶性程度高、侵袭性强、预后差、治疗难度大等特点。随着对ASC发病机制的深入研究,不断有新的治疗策略被开发出来。目前对于ASC患者以铂为基础的双药化疗及针对EGFR、ALK等驱动基因突变的靶向治疗均取得了显著的疗效,此外,免疫治疗也为ASC患者带来了新的治疗选择。虽然现有的多种治疗手段为ASC提供了多样化的干预路径,患者的预后状况却依然不尽人意。因此,本综述将简要概述ASC患者的当前治疗现状,并结合最新临床研究进展,旨在为未来的治疗策略提供新的启示和方向。Adenosquamous Carcinoma of the Lung (ASC), a unique and uncommon variant of Non-Small Cell Lung Cancer (NSCLC), is noted for its high degree of malignancy, aggressive invasiveness, unfavorable prognosis and the complexity of its treatment. With in-depth research into the pathogenesis of ASC, novel therapeutic strategies are continuously being developed. Currently, platinum-based doublet chemotherapy and targeted therapy directed at driver gene mutations such as EGFR and ALK have achieved significant therapeutic effects in patients with ASC. Additionally, immunotherapy has also brought new treatment options for patients with ASC. Despite the availability of various therapeutic approaches that provide diverse intervention pathways for ASC, the prognosis of patients remains unsatisfactory. Therefore, this review will briefly outline the current treatment status of ASC. By incorporating the latest clinical research advancements, this review aims to provide new insights and directions for future therapeutic strategies.
暂无评论